Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

A Critical Role for Patient Education in Improving Patient-Provider Communication and Treatment Decisions across Rare Hematologic Malignancies

Tariqa A Ackbarali, PhDc), Robert J. Kreitman, MD, David P. Steensma, MD, Steven M. Horwitz, MD, Wendy Turell, Kathryn Pucci, MBA

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-141646

Published: 2020

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Gaurav K. Gupta, MD, Xiaoping Sun, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Robert J. Kreitman, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4859.

https://doi.org/10.1182/blood-2018-99-116258

Published: 2018

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2018) 132 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2018-99-113419

Published: 2018

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Robert J. Kreitman, MD, Farhad Ravandi, MD, Charles Schiffer, Timothy G. Call, MD, Gerard Lozanski, MD, Pamela Harris, MD, Jennifer Sexton, Amy S Ruppert, MAS, Michael R. Grever

Blood (2016) 128 (22): 1215.

https://doi.org/10.1182/blood.V128.22.1215.1215

Published: 2016

Journal Articles

Increased Expression of Myc in Hairy Cell Leukemia, and Cell-Sensitivity to JQ1

Evgeny Arons, PhD, Hong Zhou, Yonghong Wang, PhD, Daniel Edelman, PhD, Robert J. Kreitman, MD, Holly S Stevenson, Josh J Waterfall, PhD, Paul S. Meltzer, MD PhD

Blood (2016) 128 (22): 5112.

https://doi.org/10.1182/blood.V128.22.5112.5112

Published: 2016

Journal Articles

Molecular Evidence of Ongoing Antigen Driven Somatic Hypermutation in the Natural History of Classic and Variant Hairy Cell Leukemia

Evgeny Arons, PhD, Sarah Davies, Katherine Still, Nathan Chai, Katherine Potocka, Hong Zhou, Robert J. Kreitman, MD

Blood (2015) 126 (23): 2648.

https://doi.org/10.1182/blood.V126.23.2648.2648

Published: 2015

Journal Articles

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Robert J. Kreitman, MD, Evgeny Arons, PhD, Martin S Tallman, MD, Robak Tadeusz, MD PhD, Steven Coutre, MD, Wyndham H Wilson, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Lanasa, MD PhD, David JP FitzGerald, PhD, Ira Pastan, MD

Blood (2015) 126 (23): 4161.

https://doi.org/10.1182/blood.V126.23.4161.4161

Published: 2015

Journal Articles

Minimal Residual Disease By Patient-Specific Taqman Real Time PCR in Newly Diagnosed Hairy Cell Leukemia Patients Randomized to Initial Vs Delayed Rituximab in Combination with Cladribine

Evgeny Arons, PhD, Katherine Still, BS, Sarah Davies, BS, Hong Zhou, BS, Robert J. Kreitman, MD

Blood (2014) 124 (21): 1747.

https://doi.org/10.1182/blood.V124.21.1747.1747

Published: 2014

Journal Articles

Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders

Neha Korde, MD, Sham Mailankody, MD, Evgeny Arons, PhD, Raul C. Braylan, MD, Mark Raffeld, MD, Elizabeth Maestri, RN, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Ola Landgren, MD PhD, Irina Maric, MD, Robert J. Kreitman, MD

Blood (2014) 124 (21): 5647.

https://doi.org/10.1182/blood.V124.21.5647.5647

Published: 2014

Journal Articles

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, MD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H Wilson, MD, PhD, David J. P. FitzGerald, PhD, Ira Pastan, MD

Blood (2013) 122 (21): 2871.

https://doi.org/10.1182/blood.V122.21.2871.2871

Published: 2013

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Mariela Sivina, PhD, Robert J. Kreitman, MD, Evgeny Arons, PhD, Joseph J. Buggy, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 1802.

https://doi.org/10.1182/blood.V120.21.1802.1802

Published: 2012

Journal Articles

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Robert J. Kreitman, MD, Evgeny Arons, PhD, Sapolsky Jeffrey, Laura Roth, Hong Zhou, BS, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Mark Raffeld, MD, David J. P. FitzGerald, PhD, Ji Fei, PhD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2012) 120 (21): 2896.

https://doi.org/10.1182/blood.V120.21.2896.2896

Published: 2012

Journal Articles

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Evgeny Arons, PhD, Laura Roth, Sharon Adams, CHS, Jeffery Sapolsky, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2012) 120 (21): 2488.

https://doi.org/10.1182/blood.V120.21.2488.2488

Published: 2012

Journal Articles

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

Robert J. Kreitman, MD, Rajat Singh, Maryalice Stetler-Stevenson, MD, PhD, Thomas A. Waldmann, MD, Ira Pastan, MD

Blood (2011) 118 (21): 2575.

https://doi.org/10.1182/blood.V118.21.2575.2575

Published: 2011

Journal Articles

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Robert J. Kreitman, MD, Liqiang Xi, MD, Winnifred Navarro, BS, Maryalice Stetler-Stevenson, MD, PhD, Evgeny Arons, PhD, Mark Raffeld, MD

Blood (2011) 118 (21): 931.

https://doi.org/10.1182/blood.V118.21.931.931

Published: 2011

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

NARROW

A Critical Role for Patient Education in Improving Patient-Provider Communication and Treatment Decisions across Rare Hematologic Malignancies

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Increased Expression of Myc in Hairy Cell Leukemia, and Cell-Sensitivity to JQ1

Molecular Evidence of Ongoing Antigen Driven Somatic Hypermutation in the Natural History of Classic and Variant Hairy Cell Leukemia

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Minimal Residual Disease By Patient-Specific Taqman Real Time PCR in Newly Diagnosed Hairy Cell Leukemia Patients Randomized to Initial Vs Delayed Rituximab in Combination with Cladribine

Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only